Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

por Wang, Chen, McGraw, Kathy L., McLemore, Amy F., Komrokji, Rami, Basiorka, Ashley A., Al Ali, Najla, Lancet, Jeffrey E., Padron, Eric, Kosmider, Olivier, Fontenay, Michaela, Fenaux, Pierre, List, Alan F., Sallman, David A.
Publicado 2021

Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes

por McLemore, Amy F., Hou, Hsin-An, Meyer, Benjamin S., Lam, Nghi B., Ward, Grace A., Aldrich, Amy L., Rodrigues, Matthew A., Vedder, Alexis, Zhang, Ling, Padron, Eric, Vincelette, Nicole D., Sallman, David A., Abdel-Wahab, Omar, List, Alan F., McGraw, Kathy L.
Publicado 2022

Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes

por Ward, Grace A., Dalton, Robert P., Meyer, Benjamin S., McLemore, Amy F., Aldrich, Amy L., Lam, Nghi B., Onimus, Alexis H., Vincelette, Nicole D., Trinh, Thu Le, Chen, Xianghong, Calescibetta, Alexandra R., Christiansen, Sean M., Hou, Hsin-An, Johnson, Joseph O., Wright, Kenneth L., Padron, Eric, Eksioglu, Erika A., List, Alan F.
Publicado 2023

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

por Sallman, David A., DeZern, Amy E., Garcia-Manero, Guillermo, Steensma, David P., Roboz, Gail J., Sekeres, Mikkael A., Cluzeau, Thomas, Sweet, Kendra L., McLemore, Amy, McGraw, Kathy L., Puskas, John, Zhang, Ling, Yao, Jiqiang, Mo, Qianxing, Nardelli, Lisa, Al Ali, Najla H., Padron, Eric, Korbel, Greg, Attar, Eyal C., Kantarjian, Hagop M., Lancet, Jeffrey E., Fenaux, Pierre, List, Alan F., Komrokji, Rami S.
Publicado 2021